Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Gefitinib in Patients With Recurrent or Progressive Supratentorial Malignant Gliomas or Brain or Spinal Meningiomas

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Completed	18 and over	NCI	ABTC-0001 NABTC-0001, NCT00025675, NABTC-00-01

Trial Description

Purpose:

Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors.

Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent or progressive CNS tumors.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• Measurable disease
• At least 1 week since interferon, thalidomide, tamoxifen, surgery, or isotretinoin
• At least 2 weeks since chemotherapy
• At least 4 weeks since radiation therapy
• No previous gefitinib
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive gefitinib by mouth once a day for as long as benefit is shown. Patients will be evaluated at 2 weeks.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

North American Brain Tumor Consortium

Frank Lieberman, MD, Protocol chair		Ph: 412-692-2600 Email: liebermanf@upmc.edu

Registry Information
Official Title		ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progessive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs
Trial Start Date		2002-01-03
Trial Completion Date		2009-06-02
Registered in ClinicalTrials.gov		NCT00025675
Date Submitted to PDQ		2001-08-29
Information Last Verified		2005-05-04
NCI Grant/Contract Number		U01-CA62399

Back to Top